GLP-1 Medications for Obstructive Sleep Apnea (OSA)

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea (OSA) is a chronic condition in which the upper airway repeatedly collapses during sleep, causing breathing to stop and start throughout the night. These interruptions, called apneas and hypopneas, reduce blood oxygen levels and fragment sleep. OSA severity is measured by the apnea-hypopnea index (AHI), which counts the average number of breathing disruptions per hour of sleep. An AHI of 15 to 29 is classified as moderate, and 30 or above is classified as severe.

OSA affects an estimated 25 to 30 million adults in the United States, and obesity is the single strongest risk factor. Excess weight, particularly around the neck and upper airway, increases tissue pressure on the airway during sleep, making collapse more likely. Untreated OSA is associated with elevated risks of hypertension, heart failure, stroke, type 2 diabetes, and daytime fatigue that impairs quality of life and increases accident risk.

The standard first-line treatment for moderate-to-severe OSA is continuous positive airway pressure (CPAP), a device that delivers pressurized air through a mask to keep the airway open during sleep. While CPAP is effective when used consistently, adherence remains a significant challenge. Studies suggest that roughly 30 to 50 percent of patients prescribed CPAP do not use it regularly, often due to discomfort, mask fit issues, or claustrophobia.

FDA Approval of Zepbound for OSA

On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first medication indicated for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This approval made Zepbound the only pharmaceutical treatment specifically indicated for OSA, marking a significant shift in how the condition may be managed.

Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, administered as a once-weekly subcutaneous injection. It was previously approved in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The OSA indication expanded its approved uses.

The FDA's approval was based on the SURMOUNT-OSA clinical trial program, which evaluated tirzepatide specifically in patients with OSA and obesity.

Clinical Trial Data: The SURMOUNT-OSA Trials

The approval was supported by two randomized, double-blind, placebo-controlled trials known as SURMOUNT-OSA Trial 1 and SURMOUNT-OSA Trial 2.

SURMOUNT-OSA Trial 1 enrolled patients with moderate-to-severe OSA and obesity who were not using or were unwilling to use CPAP therapy. SURMOUNT-OSA Trial 2 enrolled patients with moderate-to-severe OSA and obesity who were using CPAP therapy and continued to use it during the study. Both trials lasted 52 weeks.

In Trial 1, patients receiving tirzepatide (at doses up to 15 mg weekly) experienced a mean reduction in AHI of approximately 25 events per hour compared to roughly 5 events per hour in the placebo group. This represents a clinically meaningful reduction in the frequency of breathing disruptions during sleep.

In Trial 2, among patients already using CPAP, tirzepatide provided additional AHI reductions beyond what CPAP alone achieved. Participants on tirzepatide also experienced significant weight loss, with a mean body weight reduction of approximately 18 to 20 percent from baseline across both trials.

Beyond AHI improvements, trial participants receiving tirzepatide reported improvements in daytime sleepiness as measured by patient-reported outcome tools, as well as reductions in systolic blood pressure and improvements in markers of sleep quality. The weight loss achieved through tirzepatide is believed to be the primary mechanism by which the drug reduces OSA severity, as reduced body fat around the upper airway decreases the mechanical forces that cause airway collapse.

Who May Qualify for Zepbound for OSA

Based on the FDA-approved indication, Zepbound for OSA is indicated for adults who have moderate-to-severe obstructive sleep apnea (generally defined as an AHI of 15 or greater, confirmed by a sleep study) and obesity (generally a BMI of 30 or greater).

Patients should have a confirmed OSA diagnosis from a polysomnography (in-lab sleep study) or home sleep apnea test before starting treatment. Zepbound for OSA is not indicated for mild OSA or for patients who are not obese, as the clinical trials specifically studied the moderate-to-severe and obese population.

As with any GLP-1 receptor agonist, Zepbound carries warnings regarding the risk of thyroid C-cell tumors (based on animal studies), pancreatitis, gallbladder problems, and gastrointestinal side effects including nausea, diarrhea, and vomiting. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients should discuss their full medical history with a healthcare provider to determine whether Zepbound is appropriate for them.

Zepbound vs Other GLP-1 Medications for OSA

It is important to understand that Zepbound is currently the only GLP-1 receptor agonist with an FDA-approved indication for obstructive sleep apnea. Other GLP-1 medications such as Wegovy (semaglutide), Ozempic (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide, indicated for type 2 diabetes) are not approved for the treatment of OSA.

While weight loss from any source, including other GLP-1 medications, may improve OSA symptoms as a secondary benefit, only Zepbound has been studied in dedicated OSA clinical trials and received an FDA indication for this condition. Healthcare providers may sometimes prescribe medications off-label, but patients should be aware that such use is not supported by the same level of regulatory-reviewed evidence as an approved indication.

Mounjaro contains the same active ingredient as Zepbound (tirzepatide) but is approved for type 2 diabetes management, not for OSA or weight management. The two products have different approved indications, and Mounjaro should not be used interchangeably with Zepbound for OSA treatment without medical guidance.

Limitations and Important Considerations

Zepbound is not a replacement for CPAP in all patients. The SURMOUNT-OSA trials demonstrated that tirzepatide reduced AHI significantly, but not all patients achieved complete resolution of their OSA. Some patients may still require CPAP or other interventions even while taking Zepbound. The Trial 2 data suggest that Zepbound may be used alongside CPAP for additional benefit, rather than necessarily replacing it.

Long-term data beyond 52 weeks for tirzepatide's effects on OSA are not yet available from the pivotal trials. It is not yet established whether the AHI improvements are maintained indefinitely or what happens to OSA severity if the medication is discontinued and weight is regained. Weight regain after stopping GLP-1 medications has been observed in obesity treatment studies, which could plausibly lead to a return of OSA symptoms.

Zepbound does not address all causes of OSA. While obesity is the most common contributor, anatomical factors such as a narrow airway, enlarged tonsils, or craniofacial structure also play a role. Patients whose OSA is driven primarily by anatomical rather than weight-related factors may not benefit to the same degree.

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider to discuss whether Zepbound or any other treatment is appropriate for their specific medical situation.